2022 the Japanese Society of Medical Oncology Annual Meeting

Session information

Oral Session

[O8] Oral Session 8 Lung Cancer / Thoracic Cancer 2(Immune Checkpoint Inhibitors)
【E】

Fri. Feb 18, 2022 3:05 PM - 4:35 PM Room 2 and 3 (Annex 1 and 2, 1F, Kyoto International Conference Center)

Chair:Isamu Okamoto(Research Institute for Diseases of the Chest, Kyushu University),Kazuhisa Takahashi(Department of Respiratory Medicine, Juntendo University)
Discussant:Tatsuya Yoshida(Department of Thoracic Oncology, National Cancer Center Hospital)

Naoki Inui1, Shunichi Sugawara2, Toyoaki Hida3, Tatsuya Yoshida4, Hiroshi Tanaka5, Toru Kumagai6, Terufumi Kato7, Shunsuke Teraoka8, Isamu Okamoto9, Yukio Hosomi10, Tatsuro Fukuhara11, Go Naka12, Nobuhiko Seki13, Makoto Nishio14, Yuichiro Ohe4, Tomohide Tamura15, Nobuyuki Yamamoto8, Hiroaki Akamatsu8, Shigeru Takahashi16, Kazuhiko Nakagawa17 (1.Department of Pulmonary Medicine, Hamamatsu University Hospital, 2.Department of Pulmonary Medicine, Sendai Kousei Hospital, 3.Department of Thoracic Oncology, Aichi Cancer Center, 4.Department of Thoracic Oncology, National Cancer Center Hospital, 5.Department of Internal Medicine, Niigata Cancer Center Hospital, 6.Department of Thoracic Oncology, Osaka International Cancer Institute, 7.Department of Thoracic Oncology, Kanagawa Cancer Center, 8.Internal Medicine III, Wakayama Medical University, 9.Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, 10.Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 11.Department of Respiratory Medicine, Miyagi Cancer Center, 12.Department of Respiratory Medicine, National Center for Global Health and Medicine, 13.Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, 14.Department of Thoracic Medical Oncology, Cancer Institute Hospital of JFCR, 15.Thoracic Center, St.Luke’s International Hospital, 16.Oncology Clinical Development Planning 1, Ono Pharmaceutical Co.,LTD., 17.Department of Medical Oncology, Kindai University Faculty of Medicine)

Haruhiro Saito1, Melissa L Johnson2, Byoung Chul Cho3, Alexander Luft4, Jorge A. Alatorre-Alexander5, Sarayut Lucien Geater6, Konstantin Laktionov7, Aleksandr Vasiliev8, Dmytro Trukhin9, Sang-We Kim10, Grygorii Ursol11, Maen Hussein12, Farah Louise Lim13, Cheng-Ta Yang14, Luiz Henrique Araujo15, Niels Reinmuth16, Xiaojin Shi17, Lynne Poole18, Solange Peters19, Edward B. Garon20, Tony Mok21 (1.Kanagawa Cancer Center, Yokohama, Japan, 2.Sarah Cannon Research Institute, Tennessee Oncology, PLLCC, Nashville, TN, USA, 3.Yonsei Cancer Center, Seoul, Korea, 4.Leningrad Regional Clinical Hospital, St Petersburg, Russia, 5.Health Pharma Professional Research, Mexico City, Mexico, 6.Prince of Songkla University, Songkhla, Thailand, 7.Federal State Budgetary Institution “N.N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russia, 8.“Private Health Institution “Clinical Hospital” RZD-Medicine”, St Petersburg, Russia, 9.Odessa Regional Oncological Dispensary, Odessa, Ukraine, 10.Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, 11.Acinus, Kropyvnytskyi, Ukraine, 12.Florida Cancer Specialists – Sarah Cannon Research Institute, Leesburg, FL, USA, 13.Queen Mary University of London, London, United Kingdom, 14.Chang Gung Memorial Hospital, Taoyuan City, Taiwan, 15.Instituto Nacional de Cancer-INCA, Rio de Janeiro, Brazil, 16.Asklepios Lung Clinic, Munich-Gauting, Germany, 17.AstraZeneca, Gaithersburg, MD, USA, 18.AstraZeneca, Cambridge, UK, 19.Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland, 20.David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, 21.Chinese University of Hong Kong, Hong Kong, China)

Takayasu Kurata1, James Chih-Hsin Yang2, Isamu Okamoto3, Li Zhang4, Jie Hu5, Donglin Wang6, Chengping Hu7, Jianying Zhou8, Lin Wu9, Lejie Cao10, Jiwei Liu11, Helong Zhang12, Hong Sun13, Ziping Wang14, Hongjun Gao15, Yan Yan16, Suijun Xiao16, Jianxin Lin17, M. Catherine Pietanza17, Ying Cheng18 (1.Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan, 2.Department of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Republic of China, 3.Kyushu University Hospital, Fukuoka, Japan, 4.Respiratory Medicine Department, Peking Union Medical College Hospital, Beijing, China, 5.Department of Pulmonary Medicine, Zhongshan Hospital Fudan University, Shanghai, China, 6.Department of Oncology, Chongqing Cancer Hospital, Chongqing, China, 7.Department of Respirology and Critical Care Medicine, Xiangya Hospital Central South University, Changsha, China, 8.Department of Respiratory Diseases, The First Affiliated Hospital of Zhejiang University, Hangzhou, China, 9.Department of Thoracic Medicine, Hunan Cancer Hospital, Changsha, China, 10.Department of Respiration, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, China, 11.Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, China, 12.Department of Oncology, Tang Du Hospital, The Fourth Military Medical University, Xi'an, China, 13.Department of Oncology, The First Affiliated Hospital of Xi’An Jiaotong University, Xi'an, China, 14.Department of Thoracic Medical Oncology, Beijing Cancer Hospital, Beijing, China, 15.Department of Pulmonary Oncology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China, 16.MSD, Shanghai, China, 17.Merck & Co., Inc., Kenilworth, NJ, USA, 18.Department of Medical Oncology, Jilin Cancer Hospital, Chaoyang Borough, Changchun, China)

Kaoru Kubota1, Byoung Chul Cho2, Vichien Srimuninnimit3, Yu Fan4, Jianying Zhou5, Li Zhang6, Qing Zhou7,8, Yukio Hosomi9, Hiroaki Takeoka10, Rinee Mukherjee11, Wei Fu11, Fabricio Souza11, Tony S. K. Mok12, Li Zhang13 (1.Department of Pulmonary Medicine and Oncology, Nippon Medical School Hospital, Tokyo, Japan, 2.Division of Medical Oncology, Yonsei Cancer Center, Seoul, South Korea, 3.Department of Medicine, Siriraj Hospital, Bangkok, Thailand, 4.Thoracic Medical Oncology Department of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China, 5.Department of Respiratory Diseases, The First Affiliated Hospital of Zhejiang University, Hangzhou, China, 6.Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, 7.Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Lung Cancer Institute, Guangzhou, China, 8.Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China, 9.Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan, 10.Department of Respiratory Medicine, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan, 11.Merck & Co., Inc., Kenilworth, NJ, USA, 12.Clinical Oncology, State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Shatin, Hong Kong, China, 13.Peking Union Medical College Hospital, Beijing, China)

Nobukazu Fujimoto1, Solange Peters2, Arnaud Scherpereel3, Robin Cornelissen4, Youssef Oulkhouir5, Laurent Greillier6, Muhammet Ali Kaplan7, Toby Talbot8, Isabelle Monnet9, Sandrine Hiret10, Paul Baas11, Anna K. Nowak12, Anne S. Tsao13, Aaron S. Mansfield14, Sanjay Popat15, Xiaoqing Zhang16, Nan Hu16, David Balli16, Jenine Sanzari16, Gerard Zalcman17 (1.Department of Medical Oncology, Okayama Rosai Hospital, 2.Lausanne University Hospital, Lausanne, Switzerland, 3.University of Lille, CHU Lille, INSERM, OncoThAI, Lille, France, 4.Erasmus MC Cancer Institute, Rotterdam, Netherlands, 5.Hôpital Côte de Nacre CHU Caen, Caen, France, 6.Aix Marseille University, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Marseille, France, 7.Dicle University, Diyarbakir, Turkey, 8.Royal Cornwall Hospitals NHS Trust, Truro, UK, 9.Centre Hospitalier Intercommunal de Creteil, Créteil, France, 10.Institut de Cancérologie de l'Ouest, Saint-Herblain Cedex, France, 11.Netherlands Cancer Institute and Leiden University Medical Center, Amsterdam, Netherlands, 12.University of Western Australia and Sir Charles Gairdner Hospital, Perth, Australia, 13.MD Anderson Cancer Center, Houston, TX, USA, 14.Mayo Clinic, Rochester, MN, USA, 15.Royal Marsden Hospital and Institute of Cancer Research, London, UK, 16.Bristol Myers Squibb, Princeton, NJ, USA, 17.Bichat-Claude Bernard University Hospital, AP-HP, Université de Paris, Paris, France)

Takashi Kijima1, Terufumi Kato2, Yasushi Goto3, Takashi Yokoi1, Kozo Kuribayashi1, Koji Mikami1, Yasuko Fuchimoto4, Shuji Murakami2, Tatsuya Yoshida3, Masae Homma5, Akira Wakana5, Kazuo Noguchi5, Nobukazu Fujimoto6 (1.Department of Respiratory Medicine and Hematology, Hyogo College of Medicine, 2.Department of Thoracic Oncology, Kanagawa Cancer Center, 3.Department of Thoracic Oncology, National Cancer Center Hospital, 4.Department of Respiratory Medicine, Okayama Rosai Hospital, 5.MSD K.K., Tokyo, Japan, 6.Department of Medical Oncology, Okayama Rosai Hospital)